Justina Petrullo

If biosimilars are introduced to Spain, they will most likely save money in the pharmacological budget, according to a budget impact analysis model.

Here are the top 5 biosimilar articles for the week of May 29, 2023.

Here are the top 5 biosimilar articles for the week of May 22, 2023.

Findings from a recent study emphasize the need for improvement and changes regarding follow-on biologics and biosimilars in the global biosimilar market.

Here are the top 5 biosimilar articles for the week of May 15, 2023.

Here are the top 5 biosimilar articles for the week of May 8, 2023.

Here are the top 5 biosimilar articles for the week of May 1, 2023.

Biosimilar ranibizumab showed similar efficacy and safety in a recent study of the eyes of Indian patients with neovascular age-related macular degeneration.

A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.

Here are the top 5 biosimilar articles for the week of April 17, 2023.

A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.

Here are the top 5 biosimilar articles for the week of April 10, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM), Christine Baeder discussed what she believes the future holds for biosimilars, good and bad, and the questions that still surround the insulin price cap.

Here are the top 5 biosimilar articles for the week of April 3, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM) as well as chief operating officer for US generics and biosimilars at Teva Pharmaceuticals USA, Christine Baeder discusses her primary goals in this position, and the challenges that accompany them.

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Here are the top 5 biosimilar articles for the week of March 20, 2023.

Here are the top 5 biosimilar articles for the week of March 13, 2023.

Comparable safety and efficacy were found between biosimilar FYB201 compared with reference ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD).

Here are the top 5 biosimilar articles for the week of March 6, 2023.

Phase 3 study findings support a proposed natalizumab biosimilar (PB006) as the first biosimilar alternative to reference natalizumab (Tysabri) for treatment of relapsing-remitting multiple sclerosis (MS).

Here are the top 5 biosimilar articles for the week of February 27, 2023.

The American College of Rheumatology (ACR) steadfastly supports the availability of safe and effective treatments for patients at the lowest cost possible, and underscores the necessity of scientific rigor for biosimilar use and approval.

Patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) have similar positive attitudes towards biologics and both trust their specialists’ recommendations, according to a recent survey conducted in Australia.

Here are the top 5 biosimilar articles for the week of February 20, 2023.

Alex Jung and Kim Dwyer, both members of the Midwest Business Group on Health (MBGH) board of directors, discuss why employers should be ready for the explosion of biosimilars entering the market, and how they can prepare.

Here are the top 5 biosimilar articles for the week of February 13, 2023.

The first phase 4 postmarketing surveillance study for SB4 in South Korea as the first approved biosimilar of etanercept demonstrated comparable effectiveness and safety to previous SB4 evidence.

Here are the top 5 biosimilar articles for the week of February 6, 2023.

Here are the top 5 biosimilar articles for the week of January 30, 2023.